Stockscreener 앱 받기
2.02
2.49%
-0.04
전일 마감가:
$2.06
열려 있는:
$2.06
하루 거래량:
64,374
Relative Volume:
0.41
시가총액:
$56.67M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-2.1957
EPS:
-0.92
순현금흐름:
$-12.64M
1주 성능:
-2.01%
1개월 성능:
-14.88%
6개월 성능:
-10.72%
1년 성능:
-45.71%
1일 변동 폭
$1.9915
$2.06
1주일 범위
$1.91
$2.115
52주 변동 폭
$1.26
$4.05
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.0192 | 56.67M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.28 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.90 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.74 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.70 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December - MarketBeat
Geode Capital Management LLC Has $224,000 Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - Simply Wall St
FY2024 EPS Estimate for Immix Biopharma Lowered by Analyst - Defense World
HC Wainwright Predicts Weaker Earnings for Immix Biopharma - MarketBeat
Immix Biopharma Inc (IMMX-Q) QuotePress Release - The Globe and Mail
Immix Biopharma, Inc. Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - Marketscreener.com
HC Wainwright Reaffirms “Buy” Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - The Manila Times
Immix Biopharma Completes Critical Phase 1b Safety Trial for Novel AL Amyloidosis CAR-T Therapy - StockTitan
Analyst maintains Buy on Immix Biopharma on initial results of NEXICART-2 trial - Investing.com India
Analyst maintains Buy on Immix Biopharma on initial results of NEXICART-2 trial By Investing.com - Investing.com South Africa
Immix Biopharma (NASDAQ:IMMX) Given "Buy" Rating at HC Wainwright - MarketBeat
Immix Biopharma director Jason Hsu acquires shares worth $104,358 By Investing.com - Investing.com Canada
Immix Biopharma reports early success in CAR-T trial - Investing.com
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - GlobeNewswire
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 - The Bakersfield Californian
Immix Biopharma (IMMX) Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - StreetInsider.com
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 17.5% in November - MarketBeat
Immix Biopharma reports promising CAR-T therapy results - Investing.com
Terex Corp (TEX-N) QuotePress Release - The Globe and Mail
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis - GlobeNewswire
Immix Bio's NXC-201 Achieves 75% Response Rate in AL Amyloidosis Trial, Clinical Data Published in JCO - StockTitan
Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis By Investing.com - Investing.com South Africa
Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis - Investing.com
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - GlobeNewswire
Immix Biopharma (IMMX) Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - StreetInsider.com
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Yahoo Finance
Immix Bio's NXC-201 Shows Breakthrough 75% Complete Response Rate in Advanced AL Amyloidosis Trial - StockTitan
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media - GlobeNewswire
Immix Biopharma to Unveil Breakthrough CAR-T Therapy Data for AL Amyloidosis Treatment - StockTitan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Immix Bio's NXC-201 Achieves 75% Response Rate in Hard-to-Treat Blood Cancer Trial | IMMX Stock News - StockTitan
Immix Biopharma Presents Positive NXC-201 Clinical Data at - GlobeNewswire
Private Advisor Group LLC Has $51,000 Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201 - CGTLive™
Immix BiopharmaUS CAR-T trial progresses to dose expansion - Smartkarma
H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial - Investing.com
Immix Biopharma’s (IMMX) “Buy” Rating Reiterated at HC Wainwright - Defense World
XTX Topco Ltd Sells 34,534 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort - GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - StockTitan
Immix Biopharma stock hits 52-week low at $1.51 amid market challenges - Investing.com Australia
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Australia
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
4.93%
자본화:
|
볼륨(24시간):